Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor—1 Determination in Primary Breast Cancer Tissue for Individualized Therapy Concepts

This publication has 28 references indexed in Scilit:

• The urokinase plasminogen activator system as a novel target for tumour therapy
  Fibrinolysis and Proteolysis, 2000
• ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA?PAI-1 and tPA?PAI-1)
  International Journal of Cancer, 1999
• External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
  British Journal of Cancer, 1998
• The urokinase-type plasminogen activator system in cancer metastasis: A review
  International Journal of Cancer, 1997
• Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy
  Thrombosis and Haemostasis, 1997
• Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
  Breast Cancer Research and Treatment, 1993
• Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer
  Seminars in Thrombosis and Hemostasis, 1991
• Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer
  Fibrinolysis, 1990
• UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER
  The Lancet, 1989
• Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
  Cancer, 1988